Oxford – October 14, 2026 -- Brainomix has partnered with the Pulmonary Fibrosis Foundation (PFF) to test how patients and caregivers respond when its FDA-cleared, CE-marked e-Lung quantitative CT analysis is built into clinicians' assessment workflow for pulmonary fibrosis (PF) and other fibrotic interstitial lung diseases (ILD).

Oxford – September 18, 2026 -- Brainomix, an Oxford-based AI-powered medical imaging company, has been selected to join Future Fifty, the UK's invitation-only scale-up programme run by Tech Nation and Founders Forum Group.